Literature DB >> 2965131

Pharmacokinetics of teicoplanin in children.

E Tarral1, F Jehl, A Tarral, U Simeoni, H Monteil, D Willard, J Geisert.   

Abstract

A single dose of 6 mg/kg teicoplanin was infused over 10 min in six children of mean age 7 years, and a single dose of 6 mg/kg was infused over 20 min in four neonates of mean age 8.5 days. Serum sampling was performed at 0 and 10 min and at 1, 4, 12 and 24 h and thereafter 24-hourly, up to ten days. Urine was collected for each 24 h throughout the study in children. Teicoplanin was assayed by high performance liquid chromatography. Tolerability of teicoplanin was excellent both in children and in neonates. For all the patients the serum concentrations of teicoplanin followed an open two-compartment model. Mean Cmax was 48.6 +/- 16.7 mg/l (10 min) in children, and 19.6 +/- 1.05 mg/l (20 min) in neonates, and mean t1/2 beta was 20.5 +/- 5.5 h and 30.3 +/- 6.3 h, respectively. On the basis of the results dosage recommendations for children and neonates are made.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965131     DOI: 10.1093/jac/21.suppl_a.47

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

2.  Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.

Authors:  Wei Zhao; Daolun Zhang; Thomas Storme; André Baruchel; Xavier Declèves; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2015-09-05       Impact factor: 4.335

3.  Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing.

Authors:  D R Guay; W M Awni; C E Halstenson; M T Kenny; W F Keane; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of teicoplanin.

Authors:  M Rowland
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

Review 5.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 6.  Pharmacokinetics of anti-infective agents in paediatric patients.

Authors:  D R Butler; R J Kuhn; M H Chandler
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

Review 7.  Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.

Authors:  Charlotte I S Barker; Eva Germovsek; Rollo L Hoare; Jodi M Lestner; Joanna Lewis; Joseph F Standing
Journal:  Adv Drug Deliv Rev       Date:  2014-01-17       Impact factor: 15.470

Review 8.  Contribution of Population Pharmacokinetics of Glycopeptides and Antifungals to Dosage Adaptation in Paediatric Onco-hematological Malignancies: A Review.

Authors:  Stéphanie Leroux; Françoise Mechinaud-Heloury; Evelyne Jacqz-Aigrain
Journal:  Front Pharmacol       Date:  2021-04-01       Impact factor: 5.810

9.  Population pharmacokinetics of teicoplanin in children.

Authors:  V Ramos-Martín; S Paulus; S Siner; E Scott; K Padmore; P Newland; R J Drew; T W Felton; F Docobo-Pérez; B Pizer; F Pea; M Peak; M A Turner; M W Beresford; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.